Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Uplizna® (inebilizumab-cdon) – New indication
April 3, 2025 - Amgen announced the FDA approval of Uplizna (inebilizumab-cdon), for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients.
